A major strategic shift prioritizes the neoadjuvant BOT/BAL program for MSS colon cancer, backed by strong phase II data and FDA-aligned phase III trial design. Up to $340 million in financing secures operations through 2031, targeting a large, underserved market with significant clinical and commercial potential.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.